Blueprint Medicines Inks $1.25B Financing Deal in Exchange for Royalties of Avyakit, Gavreto

Retrieved on: 2022-06-30 17:11:11

Tags for this article:

Click the tags to see associated articles and topics

Blueprint Medicines Inks $1.25B Financing Deal in Exchange for Royalties of Avyakit, Gavreto. View article details on hiswai:

Excerpt

In 2020, Blueprint sold certain rights for the drug to Roche. Royalty Pharma will receive a portion of royalties on Roche's sales of Gavreto ...

Article found on: www.precisiononcologynews.com